Penn Medicine Hypertension, Lipids, and Approaches to CV Pharmacologic Risk Reduction What’s New in 2023
35 $
Format : 16 videos + 17 pdfs
File size: 5.57 GB
Date & Location
Friday, October 20, 2023, 8:00 AM – 1:50 PM, Virtual, Philadelphia, PA
Course Overview
CVD is the leading cause of death in the US. Hypertension and diabetes are among the foremost risk factors for the development of CVD, stroke, peripheral artery disease, and heart attack. This program will provide an overview of recent advances that target the underlying pathophysiology of cardiovascular disease. The focus of the program will be on the new guidelines for hypertension, DM and CKD and will discuss the advances in pharmacotherapeutics in these fields.
Target Audience
Specialties – FAMILY MEDICINE, FAMILY MEDICINE – Geriatric Medicine, INTERNAL MEDICINE, INTERNAL MEDICINE – Advanced Heart Failure and Transplant Cardiology, INTERNAL MEDICINE – Clinical Cardiac Electrophysiology, INTERNAL MEDICINE – Endocrinology, Diabetes and Metabolism, INTERNAL MEDICINE – Geriatric Medicine, INTERNAL MEDICINE – Interventional Cardiology, INTERNAL MEDICINE – Nephrology, INTERNAL MEDICINE – Sports Medicine, OBSTETRICS AND GYNECOLOGY, OBSTETRICS AND GYNECOLOGY – Maternal and Fetal Medicine, PREVENTIVE MEDICINE – Clinical Informatics, PUBLIC HEALTH AND GENERAL PREVENTIVE MEDICINE
Learning Objectives
After completing this activity, participants should be able to:
- Select appropriate medications to reduce adverse cardiovascular outcomes in high-risk and vulnerable populations
- Identify appropriate blood pressure goals and management in several special patient populations
- Review the controversies regarding the appropriate treatment of, and management of, pregnant patients at risk for CVD.
- Provide the best screening and treatment options for hypertension in young patients with hyperlipidemia
- Apply appropriate pharmacologic and non-pharmacologic approaches to cardiovascular risk prevention
+ Topics:
BP23_Brochure_v5.pdf
Clinical Case Discussion FOUNDATIONS IN CARDIOMETABOLIC PREVENTION.mp4
Clinical Case Discussion FOUNDATIONS IN CARDIOMETABOLIC PREVENTION.pdf
Clinical Case Discussion MEASUREMENTS AND MARKERS.mp4
Clinical Case Discussion MEASUREMENTS AND MARKERS.pdf
Clinical Case Discussion WHAT’S NEW IN TREATMENTS FOR CARDIOVASCULAR RISK REDUCTION..mp4
Clinical Case Discussion WHAT’S NEW IN TREATMENTS FOR CARDIOVASCULAR RISK REDUCTION..pdf
Diabetes Monitoring- What do I do With all of This Data and What are the Goals..mp4
Diabetes Monitoring- What do I do With all of This Data and What are the Goals..pdf
How do I Address Triglycerides..mp4
How do I Address Triglycerides..pdf
How do I Diagnose Insulin Resistance and Prediabetes and What do I do With the Information..mp4
How do I Diagnose Insulin Resistance and Prediabetes and What do I do With the Information..pdf
How do I Prescribe GLP-1 Agonists and to Whom..mp4
How do I Prescribe GLP-1 Agonists and to Whom..pdf
How do I Safely Introduce and Monitor SGLT-2 Inhibitors..mp4
How do I Safely Introduce and Monitor SGLT-2 Inhibitors..pdf
Novel Treatments for Resistant Hypertension- Ready for Prime Time..mp4
Novel Treatments for Resistant Hypertension- Ready for Prime Time..pdf
Should I use Watchman or DOACs for Stroke Prevention in Atrial Fibrillation..mp4
Should I use Watchman or DOACs for Stroke Prevention in Atrial Fibrillation..pdf
What are the Metabolic Consequences of Insulin Resistance and What is the Optimal LDL in These Patients..mp4
What are the Metabolic Consequences of Insulin Resistance and What is the Optimal LDL in These Patients..pdf
When are Ambulatory and Cuffless Blood Pressure Measurement Appropriate..mp4
When are Ambulatory and Cuffless Blood Pressure Measurement Appropriate..pdf
When do I Evaluate for Secondary Hypertension..mp4
When do I Evaluate for Secondary Hypertension..pdf
When do I Measure and What do I do with Polygenic Risk Scores..mp4
When do I Measure and What do I do with Polygenic Risk Scores..pdf
Which Thiazide Should I use for Treating my Patient’s Hypertension..mp4
Which Thiazide Should I use for Treating my Patient’s Hypertension..pdf
Who is Appropriate for PCSK-9 Inhibitors, Including Inclisiran..mp4
Who is Appropriate for PCSK-9 Inhibitors, Including Inclisiran..pdf
Related Products
